Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S159000
Reexamination Certificate
active
07868022
ABSTRACT:
The present invention is directed to 2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of β-secretase, also known as β-site cleaving enzyme and BACE, BACE1, Asp2 and memapsin2.
REFERENCES:
patent: 3138595 (1964-06-01), Osdene et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4675047 (1987-06-01), Serban et al.
patent: 4739056 (1988-04-01), Venuti et al.
patent: 4761416 (1988-08-01), Fried et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5580003 (1996-12-01), Malone et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5672805 (1997-09-01), Neve
patent: 5720936 (1998-02-01), Wadsworth et al.
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5850003 (1998-12-01), McLonlogue et al.
patent: 5877015 (1999-03-01), Hardy et al.
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 6037521 (2000-03-01), Sato et al.
patent: 6071903 (2000-06-01), Albright et al.
patent: 6184435 (2001-02-01), Benson et al.
patent: 6187922 (2001-02-01), Geen et al.
patent: 6211428 (2001-04-01), Singh et al.
patent: 6340783 (2002-01-01), Snow
patent: 2004/0087548 (2004-05-01), Salvati et al.
patent: 2004/0209905 (2004-10-01), Kubo et al.
patent: 2005/0171111 (2005-08-01), Angibaud et al.
patent: 2006/0074105 (2006-04-01), Ware, Jr. et al.
patent: 2009/0227581 (2009-09-01), Baxter et al.
patent: 2009/0227627 (2009-09-01), Baxter et al.
patent: 0406958 (1991-01-01), None
patent: 371564 (1995-07-01), None
patent: 1407774 (2004-04-01), None
patent: 63-196573 (1988-08-01), None
patent: 01/38315 (2001-05-01), None
patent: WO 01/38314 (2001-05-01), None
patent: WO 02/100399 (2002-12-01), None
patent: WO 2004/002253 (2004-03-01), None
patent: WO 2004/058686 (2004-07-01), None
patent: WO 2005/049585 (2005-06-01), None
patent: WO 2006/017836 (2006-02-01), None
patent: WO 2006/017844 (2006-02-01), None
patent: WO 2006/024932 (2006-03-01), None
patent: 2006/078577 (2006-07-01), None
patent: 2007/050612 (2007-05-01), None
patent: 2007/092846 (2007-08-01), None
patent: 2007/092854 (2007-08-01), None
U.S. Appl. No. 11/197,669, Baxter et al.
U.S. Appl. No. 11/197,608, Baxter et al.
U.S. Appl. No. 11/197,615, Baxter et al.
U.S. Appl. No. 11/671,703, Baxter et al.
U.S. Appl. No. 11/671,732, Baxter et al.
U.S. Appl. No. 11/552,792, Baxter et al.
Larner, A.J.: “Secretases as Therapeutic Targets in Alzheimer's Disease: Patents 2000 2004”. Expert Opinion On Therapeutic Patents, Ashley Publications, GB, vol. 14, No. 10, 2004, pp. 1403-1420, XP002404250.
Ishikawa, Kumyoshi et al. Quinazolineacetic acid Depivatives as Platelet Aggregation Inhibitors' XP 00236713, (1988).
Kienzle, Frank et al. “1,5-Dihydroimiazoquinazolinones as Blood Platelet Aggregation Inhibitors”, European Journal of Medicinal Chemistry, 17(6), 547-556, (1982).
Webb, Thomas Improved Synthesis of Symmetrical and Unsymmetrical 5,11-methandibenzo'b.f. 1,5-diazocines. Readily Available Nanoscale Structural Units, Journal of Organic Chemistry, vol. 55,No. 1, 1990, pp. 363-365.
Venuti, M.,et al. “Inhibitors of Cyclic AMP Phosphodiestrase 2 Structural Variations of N-Cyclohexyl-N-Methyl-4-(1,2,3,5,-Tetrahydro-2-0xoimiazo 2,1-B Quinazo-7-yl1-Oxybutyramides”J.MedicinalChemistry American Chemical Society, vol. 30, No. 2, 1988, pp. 303-318.
Patent Abstracts of Japan, Vo. 016, No. 160 (p. 1340) Apr. 20, 1992, JP 04 011255 (Fuji Photo Film Co.. td.) Jan. 16, 1992, p. 5, compound 20.
Citron, Trends in Pharm. Sci., vol. 25, Issue 2, Feb. 2004, 92-97.
Cole, et al., Molecular Neurodegeneration 2007, 2:22.
Ermolieff et al., Biochemistry, (2000) vol. 39, p. 12450.
El Mouedden, M. et al., (Johnson & Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica N.V., Turnhoutseweg 30, Beerse, Belg.), Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides,. Journal of Neuroscience Methods (2005), 145(1-2), pp. 97-105.
Games, D. et al., (Athena Neurosciences, Inc., South San Francisco, CA, USA), Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein, Nature (London) (1995), 373(6514), pp. 523-7 (V717F mice).
Hamaguchi, et al., Cell. Mol. Life Sci. 63 (2006) 1538-1552.
Hsiao, K. et al., (Dep. Neurology, Univ. Minnesota, Minneapolis, MN, USA), Correlative memory deficits, Aβelevation, and amyloid plaques in transgenic mice, Science (Washington, D. C.) (1996), 274(5284), pp. 99-102 (Tg2576 mice).
Kienzle, F. et. al., Chemical Abstract, 1983, vol. 98, Abstract No. 143363, (or CAPLUS Accession No. 1983:143363).
Lewczuk, P. et al., (Department of Psychiatry and Psychotherapy, Molecular Neurobiology Lab, University of Erlangen-Nuremberg, Erlangen, Germany), Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau, Neurobiology of Aging (2004), 25(3), pp. 273-281.
Lins, H. et al., (Department of Neurology, Otto-von-Guericke-University, Magdeburg, Germany), Immunoreactivities of amyloid β peptide(1-42) and total τ protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus, Journal of Neural Transmission (2004), 111(3), pp. 273-280.
Neve, R. L. et al., (Dep. Genetics, Harvard Medical School and McLean Hospital, Belmont, MA, USA), Transgenic mice expressing APP-C100 in the brain, Neurobiology of Aging (1996), 17(2), pp. 191-203 (APP-C100 mice).
Oddo, S. et al, (Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA, USA), Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction, Neuron (2003), 39(3), pp. 409-421 (APP Triple Transgenic Mice).
Olsson, A. et al., (Sahlgrenska University Hospital, Experimental Neuroscience Section, Institute of Clinical Neuroscience, Goteborg University, Moelndal, Sweden), Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients, Experimental Neurology (2003), 183(1), pp. 74-80.
Ruberti et al., (Neuroscience Program, International School for Advanced Studies (SISSA), Trieste, Italy), Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy, Journal of Neuroscience (2000), 20(7), pp. 2589-2601 (AD11 mice).
Schoonenboom, N.S. et al., Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?, Annals of Neurology (2005), 58(1), pp. 139-142.
Sirinathsinghji, D. J. S. (Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Essex, UK.), Transgenic mouse models of Alzheimer's disease, Biochemical Society Transactions (1998), 26(3), pp. 504-508.
Van Leuven, F. (Experimental Genetics Group, Center for Human Genetics, Flemish Institute for Biotechnology (VIB), K.U.Leuven, Louvain, Belg.), Single and multiple transgenic mice as models for Alzheimer's disease, Progress in Neurobiology (Oxford) (2000), 61(3), pp. 305-312.
Vanderstichele, H. et al., (Innogenetics NV, Ghent, Belg.), Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma, Amyloid (2000), 7(4), pp. 245-258.
Wahlund, L.-O et al., (Karolinska Institute, Section of Geriatric Medicine, Department of Clinical Neuroscience and Family Medicine, Huddinge University Hospital, Stockholm, Sweden), Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients, Neuroscience Letters (2003), 339(2), pp. 99-102.
Office Action mailed May 29, 2008 in U.S. Appl. No. 11/197,669.
Office Action mailed Aug. 21, 2008 in U.S. Appl. No. 11/197,669.
Office Action mailed Apr. 29, 2009 in U.S. Appl. No. 11/197,669.
Notice of Allowance mailed Dec. 8, 2009 in U.S. Appl. No. 11/197,669.
Office Action mailed May 30, 2008 in US U.S. Appl. No. 11/197,608.
Office Action mailed Aug. 20, 2008 in U.S. A
Baxter Ellen
Creighton Christopher John
Huang Yifang
Lu Tianbao
Luo Chi
Baek Bong-Sook
Janssen Pharmaceutica NV
Kwon Brian-Yong S
LandOfFree
2-amino-quinoline derivatives useful as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-amino-quinoline derivatives useful as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-amino-quinoline derivatives useful as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2653239